-->

Company Registry

Iaso Therapeutics Inc
Profile last edited on: 4/19/2022

Next generation vaccines to enhance human health and treat diseases
Year Founded
2018
First SBIR Year
2019
Latest SBIR Award
2021
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4942 Dawn Avenue Suite 108
East Lansing, MI 48823
   (517) 802-0028
   iasother@yahoo.com
   www.iasotherapeutics.com
Multiple Locations:   
Congressional District:   08
County:   Ingham

Public Profile

Iaso Therapeutics, Inc. is an early-stage start-up spun out from Michigan State University structured around development of next generation vaccines to enhance human health and treat diseases. A priority of the firm is to translate the cutting-edge technologies developed in the laboratory of one of the Founders to promote human health and treat diseases. In that vein,the company has developed a proprietary mutant bacteriophage Q? (mQ?) platform technology. Head-to-head comparison studies of mQ? against those using the benchmark carriers suggest that Iaso's mQ? conjugates can elicit more powerful immune responses. This exciting technology is being applied to vaccines against a variety of diseases including cancer and infectious diseases. Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed. Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
5-9

Awards Distribution by Agency

Key People / Management

  Robert Forgey -- President and CEO

  Xuefei Huang -- Founder and CSO

  Herbert W Kavunja --

  Soham Maity -- Postdoctoral Research Fellow

  Herbert Wanjala Kavunja -- Chief Scientist

SBIR firms in the news

There are no news available.